Objective To explore the prognostic factors of primary plasma cell leukemia(pPCL)in the era of novel agents.Methods The clinical data of 66 patients with pPCL treated at the Department of Haematology,Beijing Chao-Yang Hospital,Capital Medical University from 2011 to 2022 were retrospectively collected to analyze their prognostic factors.Results Among the 66 patients with pPCL,the median age was 59(range:29-79)years.The median overall survival(OS)duration was 19.0(95％CI 10.4-27.6)months,and the median progression-free survival(PFS)duration was 11.0(95％CI 6.5-15.6)months.The median OS and PFS were significantly longer in patients with the best post-treatment response of very good partial remission(VGPR)or better than in patients with a response of partial remission(PR)or worse(median OS:33.0 months vs 6.0 months,P＜0.001;median PFS:16.0 months vs 3.0 months,P＜0.001).OS was significantly longer in patients who underwent autologous hematopoietic stem cell transplantation than in those who did not undergo transplantation(49.0 months vs 6.0 months,P=0.002),and there was a trend toward a longer PFS in patients who underwent transplantation than in those who did not undergo transplantation(19.0 months vs 8.0 months,P=0.299).The median OS and PFS were significantly longer in patients who received maintenance therapy than in those who did not receive maintenance therapy(median OS:56.0 months vs 4.0 months,P＜0.001;median PFS:20.0 months vs 2.0 months,P＜0.001).Multivariate analysis showed that hypercalcemia was an independent risk factor(HR=3.204,95％CI 1.068-9.610,P=0.038)for patients with pPCL,while receiving maintenance therapy(HR=0.075,95％CI 0.022-0.253,P＜0.001)and post-treatment response of VGPR or better(HR=0.175,95％CI 0.048-0.638,P=0.008)were independent protective factors for patients with pPCL.Conclusions In the era of novel agents,hypercalcemia,receiving maintenance therapy,and post-treatment response of VGPR or better are independent prognostic factors for pPCL.
维普
万方数据